Table 3.
Category | Light | p value | ||||
---|---|---|---|---|---|---|
Anti-VEGF Antibody | None | Aflibercept | Ranibizumab | None | Aflibercept | |
Level | Level | Level | vs. | vs. | ||
Mean ± SD | Mean ± SD | Mean ± SD | Aflibercept | Ranibizumab | Ranibizumab | |
PDGF-BB | 2.11 ± 0.73 | 2.02 ± 0 | 1.01 ± 1.43 | 0.442 | 0.162 | 0.211 |
IL-1β | 0 | 0 | 0 | — | — | — |
IL-1ra | 11.2 ± 1.96 | 15.9 ± 1.15 | 14.0 ± 2.04 | 0.029 | 0.106 | 0.190 |
IL-2 | 0.75 ± 0.13 | 1.34 ± 0.17 | 0.90 ± 0.38 | 0.011 | 0.280 | 0.137 |
IL-4 | 0 | 0 | 0 | — | — | — |
IL-5 | 0 | 0 | 0 | — | — | — |
IL-6 | 2.88 ± 0.09 | 4.16 ± 0.47 | 3.53 ± 0.12 | 0.008 | 0.003 | 0.102 |
IL-7 | 3.61 ± 1.13 | 0.74 ± 0 | 1.66 ± 0.62 | 0.021 | 0.060 | 0.085 |
IL-8 | 19.2 ± 4.30 | 24.9 ± 0.88 | 26.1 ± 5.90 | 0.087 | 0.109 | 0.401 |
IL-9 | 2.00 ± 0.08 | 1.66 ± 0.43 | 0.71 ± 1.00 | 0.117 | 0.047 | 0.173 |
IL-10 | 0 | 0 | 0 | — | — | — |
IL-12 | 12.4 ± 0.55 | 0 | 0 | 4.02 × 10−55 | 4.02 × 10−55 | — |
IL-13 | 1.18 ± 0.11 | 0.21 ± 0.29 | 0.21 ± 0.29 | 0.006 | 0.006 | 0.550 |
IL-15 | 3.41 ± 0.23 | 4.06 ± 0.45 | 3.74 ± 0.18 | 0.058 | 0.098 | 0.226 |
IL-17A | 6.23 ± 0.87 | 7.67 ± 0.31 | 5.73 ± 1.53 | 0.061 | 0.330 | 0.110 |
Eotaxin | 0 | 0 | 0 | — | — | — |
bFGF | 99.2 ± 16.3 | 127.0 ± 22.5 | 120.4 ± 29.3 | 0.100 | 0.180 | 0.412 |
G-CSF | 0 | 0 | 0 | — | — | — |
GM-CSF | 0 | 0 | 0 | — | — | — |
IFN-γ | 0 | 0 | 0 | — | — | — |
IP-10 | 0 | 0 | 0 | — | — | — |
MCP-1 | 48.8 ± 0.99 | 55.6 ± 2.19 | 57.7 ± 0.26 | 0.008 | 0.001 | 0.154 |
MIP-1α | 0.26 ± 0 | 0.13 ± 0.18 | 0.34 ± 0.11 | 0.136 | 0.136 | 0.151 |
MIP-1β | 0.19 ± 0.17 | 0 | 0 | 0.110 | 0.110 | — |
RANTES | 0 | 0 | 0 | — | — | — |
TNFα | 0 | 0 | 0 | — | — | — |
VEGF-A | 242.2 ± 20.1 | 3.15 ± 0.42 | 47.4 ± 12.4 | 2.67 × 10−4 | 0.001 | 0.019 |
ARPE-19 cells were cultured with 0.50 mg/mL aflibercept, 0.125 mg/mL ranibizumab or neither under light irradiation for 24 h. Levels of IL-12, MCP-1 and VEGF-A were more than 10 pg/mL in at least one of the three cultures. n = 4 in each group.